RE: $6 Billion AML Treatment market opens up for HEMO27 Sep 2024 09:17
Exactly, the global pharmaceutical sector has a history of paying hundred$ of million$ and in many cases billion$ for the opportunity to shore up their R&D / sales pipelines. See below:
• AbbVie completed its acquisition of Cerevel Therapeutics in August 2024, for $8.7 billion
• Also in August 2024 Otsuka purchased Jnana Therapeutics for $800 million
• Another biggie in the last quarter was Eli Lilly buying Morphic for $3.2 billion . The deal was focused on Morphic’s main drug discovery candidate (MORF-057) for inflammatory bowel disease
• CVC Capital signed an agreement in August for Therakos at $925 Million
• MilliporeSigma acquired Mirus Bio in August for $600 million
• Boehringer Ingelheim acquired Nerio Therapeutics Inc.for $1.3 Billion in July
• Roche completed its acquisition of Carmot Therapeutics, a clinical-stage company in July, for $2.7 billion
• On July 24th Agilent Technologies signed a definitive agreement to acquire BioVectra, for $925 million
• Merck MSD purchased EyeBio in July for up to $3 Billion.
• Thermo Fisher acquired Olink in July, for $3.1 billion
• In June ANI Pharma acquired Alimera for $381 million
• June 12th saw Ono Pharmaceutical buy Deciphera Pharma for $2.4 billion
• Asahi Kasei bought Calliditas in May, 2024 for $1.1 billion
• Biogen bought HI-Bio, in May, for $1.15 billion upfront and up to $650 million in potential milestone payments
• J&J acquired Proteologix in May, for $850 million in cash
• Novartis agreed to acquire Mariana Oncology, a preclinical-stage biotechnology on May 3rd, for $1 billion upfront & a further $750 million in milestone payments
• Deciphera Pharma bought ONO Pharma in April, for $2.4 billion
• Incyte Corp acquired Escient Pharma, a clinical-stage drug discovery and development company, in April, for $750 million
• Eliem Therapeutics bought Tenet Medicines, another development-stage biotechnology company, in April for $210 million
• Vertex Pharma acquired Alpine Sciences in April for $4.9 billion
• CoreRx acquired Societal Inc (focused on small molecule therapeutics) in April for $130 million
• J&J purchased Shockwave Medical in April 2024 for $13.1 billion
• Genmab bought Profound Bio – which specialises in developing next generation treatments of certain cancers - in April for $1.8 billion
• Bora Pharm bought Upsher Smith Bio in April for $210 million
• On March 25th Novo Nordisk agreed to acquire Cardior Pharmaceuticals for $1.12 billion
• AbbVie acquired Landos in March for $137.5 million
• AZ bought Fusion Pharma on March 19, for $2.4 billion
• BMS acquired Karuna on March 18, for $14 billion
• AZ bought Amolyt a clinical-stage company in March for $1.05 billion
• Novartis acquired IFM in March for $90 million upfront plus up to $745 million in milestones
• Johnson & Johnson acquired Ambrx Biopharma Inc., a clinical-stage comp
Sign In
Follow the stocks
